US Patent

US10689377 — KRas G12C inhibitors

Method of Use · Assigned to Array Biopharma Inc · Expires 2037-05-17 · 11y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds that irreversibly inhibit the activity of KRas G12C and methods of using them.

USPTO Abstract

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

Drugs covered by this patent

Krazati (ADAGRASIB) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3490`	—	Krazati

Patent Metadata

Patent number: US10689377
Jurisdiction: US
Classification: Method of Use
Expires: 2037-05-17
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.